Related Experiment Video
Updated: Feb 5, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
[Chronic Myelogenous Leukemia]
Abstract:
The advent of tyrosine kinase inhibitors (TKI) has improved prognosis and outcome of patients with chronic myelogenous leukemia (CML) considerably. In comparison to imatinib, first line use of second generation inhibitors nilotinib, dasatinib and bosutinib lead to faster and deeper molecular remissions accompanied by a novel adverse event profile. Essential part of the management of CML patients is a consequent use of cytogenetic and molecular follow up with standardized methods to regularly assess the remission status. Long lasting remission without treatment in an important minority of patients prompted the hope for curability of CML. The use of interferon alpha in parallel with or after TKI therapy is associated with the induction of an immune response against the leukemic clone with further improved remission rate. The cooperative management of CML patients permits the early use of novel treatment options in patients at risk.
Insights
Tyrosine kinase inhibitors (TKIs) have transformed chronic myelogenous leukemia (CML) treatment, offering faster remissions. Monitoring patient response and exploring novel therapies like interferon alpha may lead to potential cures for CML.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic myelogenous leukemia (CML) management has been revolutionized by tyrosine kinase inhibitors (TKIs).
- Second-generation TKIs (nilotinib, dasatinib, bosutinib) offer improved molecular remission rates compared to imatinib.
- A unique adverse event profile is associated with newer TKIs.
Purpose of the Study:
- To review the impact of TKIs on CML prognosis and outcomes.
- To highlight the importance of molecular monitoring in CML management.
- To discuss the potential for CML curability and novel therapeutic strategies.
Main Methods:
- Review of current literature on TKI therapy in CML.
- Analysis of cytogenetic and molecular follow-up data.
- Evaluation of treatment strategies including interferon alpha.
Main Results:
- First-line use of second-generation TKIs leads to faster and deeper molecular remissions.
- Standardized monitoring is crucial for assessing remission status.
- Interferon alpha may enhance remission rates by inducing immune responses.
Conclusions:
- TKIs have significantly improved CML patient outcomes.
- Long-term remissions raise hope for CML curability.
- Cooperative management allows timely use of novel treatments for at-risk CML patients.
Related Concept Videos
01:23Chronic Pharyngitis
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:25Chronic Kidney Disease I: Introduction
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...